MedStar Health Explains HER2 Positive Breast Cancer

  Рет қаралды 6,869

MedStar Health

MedStar Health

4 жыл бұрын

HER2 Positive breast cancer is one of the most common types. Dr. Shweta Kurian, medical oncologist and hematologist at MedStar Franklin Square Medical Center and MedStar Health Bel Air Medical Campus, explains during the WMAR House Calls event. Watch this video to find out what the type is, the treatment for it and patient survival rates.
Learn more: www.medstargeorgetowncancer.o...
NOTE: The House Calls event took place on Oct. 7 & 9. The phone lines are no longer open.

Пікірлер: 6
@jules1277
@jules1277 4 жыл бұрын
Thank you, excellent information
@beenasalil3130
@beenasalil3130 3 жыл бұрын
Well explained.
@kmydesire12
@kmydesire12 2 жыл бұрын
My oncologist switched me from Tamoxifen to another medicine I forgot the name . It starts with an A.
@user-ky9lc4kt5c
@user-ky9lc4kt5c 2 ай бұрын
it is an Aromatse inhibitor, right?
Hormonal Therapy for Breast Cancer: We Teach You
13:39
Breast Cancer School for Patients
Рет қаралды 157 М.
Always be more smart #shorts
00:32
Jin and Hattie
Рет қаралды 47 МЛН
Breast Cancer Survivor Story | Doreen DiSalvo | The Patient Story
21:01
The Patient Story
Рет қаралды 25 М.
Saving Your Vision From Diabetes
3:49
Greater Baltimore Medical Center
Рет қаралды 20 М.
If You Get COVID 19: Optimize Immune System (Vitamin D, Monoclonal Antibodies, NAC, Quercetin etc.)
39:55
MedCram - Medical Lectures Explained CLEARLY
Рет қаралды 9 МЛН
Medical update: HER2-Positive and triple-positive metastatic breast cancer
51:38
Living Beyond Breast Cancer
Рет қаралды 7 М.
Stage 4 breast cancer treatment - last stage breast cancer survival in hindi 2021
13:07
New BREAST CANCER Vaccine  For Her2 Positive Patients || Dr Liz O'Riordan
4:25
Patient Story - Discovery and Treatment of Pancreatic Cancer in Baltimore
5:55
Mark Fraiman, MD - St Joseph Medical Center Liver and Pancreas Center
Рет қаралды 3,9 М.
Audiologist shares benefits of Cochlear’s Remote Check technology
5:21
Cochlear Americas
Рет қаралды 1,5 М.